Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 2/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CD38 | P28907 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15834058 | 0.85 | ADORA3 (0.37) | IRAK4JAK2JAK1KDM4ECD38 | |
| SCHEMBL15829840 | 0.81 | IRAK4 (0.51) | IRAK4MAPK1JAK2JAK1CSF1R | |
| SCHEMBL31498503 | 0.77 | MAPK1 (0.49) | IRAK4MAPK1JAK2JAK1LRRK2 | |
| SCHEMBL16217391 | 0.77 | IRAK4 (0.47) | IRAK4MAPK1JAK2JAK1CSF1R | |
| SCHEMBL16091455 | 0.77 | MAPK1 (0.49) | IRAK4MAPK1JAK2JAK1CSF1R | |
| SCHEMBL17308604 | 0.69 | MAPK1 (0.43) | IRAK4MAPK1CSF1RLRRK2KDM4E | |
| SCHEMBL15834739 | 0.69 | KDM4E (0.36) | IRAK4JAK2JAK1KDM4EADORA3 | |
| SCHEMBL19287695 | 0.69 | KDM4E (0.36) | IRAK4JAK2JAK1KDM4EADORA3 | |
| SCHEMBL9061374 | 0.68 | KDM4E (0.37) | IRAK4KDM4E | |
| SCHEMBL29944842 | 0.68 | EML4 (0.44) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10307413-B2 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10307413-B2 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT3 | IRAK4 1567/4885MAPK1 1357/4885JAK2 450/4885 |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | IRAK4 1567/4885MAPK1 1357/4885JAK2 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.